Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : A New Way to Connect Psoriatic Disease Patients with Healthcare Providers

11/17/2021 | 01:09pm EST

Like many organizations across the world, the Bath Institute for Rheumatic Disease (BIRD) was forced to adjust its approach to patient engagement due to the COVID-19 pandemic. The United Kingdom-based patient organization quickly pivoted from organizing in-person patient gatherings to expanding its virtual offerings, including a podcast series and targeted social media advertising campaigns, to reach people living with psoriatic arthritis and their caregivers in their homes.

This revamped approach saw great initial success and served as the inspiration for the organization's application to Amgen's UPLIFT Innovation Challenge, an initiative launched in partnership with the International Federation of Psoriasis Associations (IFPA). The goal of the initiative was to encourage patient organizations to develop actionable solutions for challenges faced by the psoriatic disease community and their healthcare providers, as identified by the UPLIFT survey.

With over 22 applications received from patient organizations around the globe, BIRD was selected to receive a one-time grant of $25,000 to bring their solution, "Digital Engagement for PsA Patients and Families," to the psoriatic disease community.

BIRD's proposed solution will use patient feedback to develop clinician-led webinars and create refreshed advertising to drive patients to their podcast series. "By deepening patient knowledge, we aim to change expectations around treatments and outcomes to boost patients' confidence in asking questions to the healthcare professionals who join the webinars," said Celia Mead, director of BIRD.

The webinars will include insights from patients in advance to ensure sessions cover information that is most meaningful to them and that patients are ready and confident to interact. With many people in the psoriatic disease community still not attending doctor appointments in person or waiting longer, accessibility was also key. "We want to make these webinars accessible so that during the sessions, patients, families and caregivers will be able to ask questions to better understand their condition," Mead continued.

Psoriatic arthritis patients continue to face challenges in managing and communicating the full impact of their disease with their healthcare providers - this has only increased with the COVID-19 pandemic. "We have always looked for ways to deepen patients' knowledge of their conditions, but the pandemic has caused some individuals to feel increasingly anxious and isolated," Mead explained.

BIRD's virtual webinars and digital advertising campaign aim to address these challenges directly and provide patients with a way to improve their standard of care, without leaving the comfort of their homes.

"We appreciate that companies like Amgen are launching these types of initiatives because it allows our organization to be creative and innovative in our ideas, rather than prescriptive, to ultimately support patients," Mead said.

Visit BIRD's website at www.birdbath.org.uk to learn how you can get involved.


Amgen Inc. published this content on 17 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2021 17:59:31 UTC.

ę Publicnow 2021
All news about AMGEN INC.
01/20AMGEN PLUGS IN : Electric Vehicle Pilot Program Advances Carbon Neutrality Goal
01/20Amgen Secures Japanese Approval of Non-Small Cell Lung Cancer Drug Lumakras
01/20Amgen Inc.'s LUMAKRAS Receives Approval in Japan for Patients with KRAS G12C-Mutated Ad..
01/20"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
01/19FDA Clears CytomX's Investigational New Drug Application for CX-904 in Advanced Solid T..
01/18Medicenna Therapeutics up 12.7% in US Trade, Details Management Change, Appoints Develo..
01/14AMGEN : Teneobio Acquisition Adds Talent and New Types of Antibodies to Amgen
01/13BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors
01/13BridgeBio Pharma, Amgen Team Up to Evaluate Combination Treatment for Advanced Solid Tu..
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 025 M - -
Net income 2021 5 559 M - -
Net Debt 2021 21 988 M - -
P/E ratio 2021 22,6x
Yield 2021 3,05%
Capitalization 129 B 129 B -
EV / Sales 2021 5,80x
EV / Sales 2022 5,47x
Nbr of Employees 24 300
Free-Float -
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 228,90 $
Average target price 238,36 $
Spread / Average Target 4,13%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.1.75%128 932
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833